Intel Corp. (NASDAQ: INTC) reported mixed fourth-quarter results on Thursday, beating profit expectations but guiding for weaker near-term revenue and flat earnings, highlighting the uneven progress of its turnaround. Persistent supply constraints and margin pressure weighed on the outlook, prompting a sharp selloff in the stock. Intel posted revenue of $13.67 billion, ahead of the $13.37 billion consensus, while adjusted earnings reached 15 cents per share, surpassing...
Pfizer Inc. (NYSE: PFE) CEO Albert Bourla sharply criticized Robert F. Kennedy's views on vaccines, calling them "anti-science." He suggested that meaningful progress on immunization policy would require a change in leadership at the U.S. Department of Health and Human Services.
Speaking Wednesday at a Wall Street Journal event during the World Economic Forum in Davos, Switzerland, Bourla said discussions with Kennedy break down when vaccines enter the conversation, despite productive exchanges on other healthcare topics.
Bourla told WSJ that talks around cancer research and pharmaceutical pricing have been constructive, but vaccine-related discussions are fundamentally different.
He described Kennedy's stance as rigid and ideological, saying it resembles a belief system rather than a scientific debate.
When asked directly what would need to change for vaccine discussions to move forward, Bourla gave a blunt response: 'the health secretary.' He did not elaborate further but made clear that leadership at the top of U.S. health policy is, in his view, a central obstacle.
Beyond vaccines, Bourla also aimed at actions by President Trump's administration that reduced funding for U.S. universities. He warned that these decisions have weakened America's position in global health research at a time when China is rapidly advancing.
China Factor
